CONV 01-alpha is under clinical development by Convergent Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CONV 01-alpha’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CONV 01-alpha overview
CONV 01-alpha (225Ac−J591) is under development for the treatment of metastatic castration−resistant prostate cancer (CRPC). The drug candidate is a radio labeled (actinium-225) humanized monoclonal antibody administered as an intravenous route. It targets prostate specific membrane antigen (PSMA).
Convergent Therapeutics overview
Convergent Therapeutics is a pharmaceutical company, developing next-generation radiopharmaceutical therapy for prostate cancer and other applications. It is headquartered in New York City, New York, the US.
For a complete picture of CONV 01-alpha’s drug-specific PTSR and LoA scores, buy the report here.